Adenoviral virotherapy for malignant brain tumors

Bibliography

• Thorsen F, Tysnes BB. Brain tumor cell invasion, anatomical and biological considerations. Anticancer Res 1997;17(6B):4121-6
   PubMed Web of Science ®Google Scholar
• Chang JE, Khuntia D, Robins HI, Mehta MP. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. Clin Adv Hematol Oncol 2007;5(11):894-902, 7-15
   PubMedGoogle Scholar
• Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008;26(17):2839-45
   PubMed Web of Science ®Google Scholar
• Hulleman E, Helin K. Molecular mechanisms in gliomagenesis. Adv Cancer Res 2005;94:1-27
   PubMed Web of Science ®Google Scholar
• Das A, Tan WL, Teo J, Smith DR. Expression of survivin in primary glioblastomas. J Cancer Res Clin Oncol 2002;128(6):302-6
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352(10):997-1003
   PubMed Web of Science ®Google Scholar
• Mcgirt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009;110(3):583-8
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003;5(2):79-88
   PubMed Web of Science ®Google Scholar
• Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995;345(8956):1008-12
   PubMed Web of Science ®Google Scholar
• Aksel IS, Aykan TB. Growth behavior of the rabies virus in a glioblastomatous tumor induced with methylcholanthrene in mice. World Neurol 1961;2:398-405
   PubMedGoogle Scholar
• Mannweiler K, Palacios O. Cultivation and reproduction of herpes simplex virus in nervous system cell cultures. Acta Neuropathol 1969;12(3):276-99
   PubMed Web of Science ®Google Scholar
• Nakamura K, Homma M, Ishida N. Growth of measles virus in cultures of rat glioma cells. Infect Immun 1975;12(3):614-20
   PubMed Web of Science ®Google Scholar
• Fleury H, Pasquier PD. Replication of measles virus in a cell culture from a glioblastoma of human origin. J Neuropathol Exp Neurol 1977;36(5):842-5
   PubMed Web of Science ®Google Scholar
• Adler R, Glorioso JC, Levine M. Infection by herpes simplex virus and cells of nervous system origin: characterization of a non-permissive interaction. J Gen Virol 1978;39(1):9-20
   PubMed Web of Science ®Google Scholar
• Tsiang H, Koulakoff A, Bizzini B, Berwald-netter Y. Neurotropism of rabies virus. An in vitro study. J Neuropathol Exp Neurol 1983;42(4):439-52
   PubMed Web of Science ®Google Scholar
• Yumitori K, Handa H, Yamashita J, et al. Treatment of malignant glioma with mumps virus (author's transl). No Shinkei Geka 1982;10(2):143-7
   PubMedGoogle Scholar
• Martuza RL, Malick A, Markert JM, et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991;252(5007):854-6
   PubMed Web of Science ®Google Scholar
• Markert JM, Malick A, Coen DM, Martuza RL. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 1993;32(4):597-603
   PubMed Web of Science ®Google Scholar
• Markert JM, Parker JN, Buchsbaum DJ, et al. Oncolytic HSV-1 for the treatment of brain tumours. Herpes 2006;13(3):66-71
   PubMedGoogle Scholar
• Oldfield EH, Ram Z, Culver KW, et al. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 1993;4(1):39-69
   PubMed Web of Science ®Google Scholar
• Raffel C, Culver K, Kohn D, et al. Gene therapy for the treatment of recurrent pediatric malignant astrocytomas with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum Gene Ther 1994;5(7):863-90
   PubMed Web of Science ®Google Scholar
• Rainov NG. A Phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000;11(17):2389-401
   PubMed Web of Science ®Google Scholar
• Rainov NG, Ren H. Clinical trials with retrovirus mediated gene therapy–what have we learned? J Neurooncol 2003;65(3):227-36
   PubMed Web of Science ®Google Scholar
• Phuong LK, Allen C, Peng KW, et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003;63(10):2462-9
   PubMed Web of Science ®Google Scholar
• Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998;282(5392):1332-4
   PubMed Web of Science ®Google Scholar
• Yang WQ, Lun X, Palmer CA, et al. Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clin Cancer Res 2004;10(24):8561-76
   PubMed Web of Science ®Google Scholar
• Mizuno M, Yoshida J, Colosi P, Kurtzman G. Adeno-associated virus vector containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration. Jpn J Cancer Res 1998;89(1):76-80
   PubMedGoogle Scholar
• Csatary LK, Bakacs T. Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. JAMA 1999;281(17):1588-9
   PubMed Web of Science ®Google Scholar
• Russell SJ. RNA viruses as virotherapy agents. Cancer Gene Ther 2002;9(12):961-6
   PubMed Web of Science ®Google Scholar
• Ren H, Boulikas T, Lundstrom K, et al. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene–a Phase I/II clinical protocol. J Neurooncol 2003;64(1-2):147-54
   PubMed Web of Science ®Google Scholar
• Gridley DS, Andres ML, Li J, et al. Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy. Int J Oncol 1998;13(5):1093-8
   PubMed Web of Science ®Google Scholar
• Timiryasova TM, Chen B, Haghighat P, Fodor I. Vaccinia virus-mediated expression of wild-type p53 suppresses glioma cell growth and induces apoptosis. Int J Oncol 1999;14(5):845-54
   PubMed Web of Science ®Google Scholar
• Chen B, Timiryasova TM, Haghighat P, et al. Low-dose vaccinia virus-mediated cytokine gene therapy of glioma. J Immunother 2001;24(1):46-57
   PubMed Web of Science ®Google Scholar
• Gromeier M, Lachmann S, Rosenfeld MR, et al. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci USA 2000;97(12):6803-8
   PubMed Web of Science ®Google Scholar
• Jackson CA, Cobbs C, Peduzzi JD, et al. Repetitive intrathecal injections of poliovirus replicons result in gene expression in neurons of the central nervous system without pathogenesis. Hum Gene Ther 2001;12(15):1827-41
   PubMed Web of Science ®Google Scholar
• Nabel GJ. Development of optimized vectors for gene therapy. Proc Natl Acad Sci USA 1999;96(2):324-6
   PubMed Web of Science ®Google Scholar
• Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275(5304):1320-3
   PubMed Web of Science ®Google Scholar
• Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997;94(7):3352-6
   PubMed Web of Science ®Google Scholar
• Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment. Cell 1993;73(2):309-19
   PubMed Web of Science ®Google Scholar
• Kim M, Sumerel LA, Belousova N, et al. The coxsackievirus and adenovirus receptor acts as a tumour suppressor in malignant glioma cells. Br J Cancer 2003;88(9):1411-6
   PubMed Web of Science ®Google Scholar
• Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998;72(12):9706-13
   PubMed Web of Science ®Google Scholar
• Lamfers ML, Grill J, Dirven CM, et al. Potential of the conditionally replicative adenovirus Ad5-Δ24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 2002;62(20):5736-42
   PubMed Web of Science ®Google Scholar
• Wickham TJ, Tzeng E, Shears LL, et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997;71(11):8221-9
   PubMed Web of Science ®Google Scholar
• Staba MJ, Wickham TJ, Kovesdi I, Hallahan DE. Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models. Cancer Gene Ther 2000;7(1):13-9
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Li H, Lam JT, et al. Substitution of the adenovirus serotype 5 knob with a serotype 3 knob enhances multiple steps in virus replication. Cancer Res 2003;63(6):1262-9
   PubMed Web of Science ®Google Scholar
• Takayama K, Reynolds PN, Short JJ, et al. A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropism. Virology 2003;309(2):282-93
   PubMed Web of Science ®Google Scholar
• Zheng S, Ulasov IV, Han Y, et al. Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma. J Gene Med 2007;9(3):151-60
   PubMed Web of Science ®Google Scholar
• Ulasov IV, Rivera AA, Han Y, et al. argeting adenovirus to CD80 and CD86 receptors increases gene transfer efficiency to malignant glioma cells. J Neurosurg 2007;107(3):617-27
   PubMed Web of Science ®Google Scholar
• Tsuruta Y, Pereboeva L, Glasgow JN, et al. Reovirus sigma1 fiber incorporated into adenovirus serotype 5 enhances infectivity via a CAR-independent pathway. Biochem Biophys Res Commun 2005;335(1):205-14
   PubMed Web of Science ®Google Scholar
• Paul CP, Everts M, Glasgow JN, et al. Characterization of infectivity of knob-modified adenoviral vectors in glioma. Cancer Biol Ther 2008;7(5):786-93
   PubMed Web of Science ®Google Scholar
• Perreau M, Mennechet F, Serratrice N, et al. Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy. J Virol 2007;81(7):3272-84
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S, Rich JN. Designer therapies for glioblastoma multiforme. Ann NY Acad Sci 2008;1142:108-32
   PubMed Web of Science ®Google Scholar
• van Beusechem VW, Mastenbroek DC, van den Doel PB, et al. Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. Gene Ther 2003;10(23):1982-91
   PubMed Web of Science ®Google Scholar
• Wang W, Zhu NL, Chua J, et al. Retargeting of adenoviral vector using basic fibroblast growth factor ligand for malignant glioma gene therapy. J Neurosurg 2005;103(6):1058-66
   PubMed Web of Science ®Google Scholar
• Voelzke WR, Petty WJ, Lesser GJ. Targeting the epidermal growth factor receptor in high-grade astrocytomas. Curr Treat Options Oncol 2008;9(1):23-31
   PubMed Web of Science ®Google Scholar
• Sonabend AM, Dana K, Lesniak MS. Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma. Expert Rev Anticancer Ther 2007;7(Suppl 12):S45-50
   PubMed Web of Science ®Google Scholar
• Frost E, Williams J. Mapping temperature-sensitive and host-range mutations of adenovirus type 5 by marker rescue. Virology 1978;91(1):39-50
   PubMed Web of Science ®Google Scholar
• Fueyo J, Alemany R, Gomez-manzano C, et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 2003;95(9):652-60
   PubMed Web of Science ®Google Scholar
• Manome Y, Wen PY, Chen L, et al. Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide. Gene Ther 1996;3(6):513-20
   PubMed Web of Science ®Google Scholar
• Chen J, Bezdek T, Chang J, et al. A glial-specific, repressible, adenovirus vector for brain tumor gene therapy. Cancer Res 1998;58(16):3504-7
   PubMed Web of Science ®Google Scholar
• Lammering G, Hewit TH, Valerie K, et al. Anti-erbB receptor strategy as a gene therapeutic intervention to improve radiotherapy in malignant human tumours. Int J Radiat Biol 2003;79(7):561-8
   PubMed Web of Science ®Google Scholar
• Lammering G, Lin PS, Contessa JN, et al. Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells. Int J Radiat Oncol Biol Phys 2001;51(3):775-84
   PubMed Web of Science ®Google Scholar
• Su ZZ, Lebedeva IV, Sarkar D, et al. Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner. Oncogene 2003;22(8):1164-80
   PubMed Web of Science ®Google Scholar
• Smitt PS, Driesse M, Wolbers J, et al. Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol Ther 2003;7(6):851-8
   PubMed Web of Science ®Google Scholar
• Kang YA, Shin HC, Yoo JY, et al. Novel cancer antiangiotherapy using the VEGF promoter-targeted artificial zinc-finger protein and oncolytic adenovirus. Mol Ther 2008;16(6):1033-40
   PubMed Web of Science ®Google Scholar
• Zhang WW, Alemany R, Wang J, et al. Safety evaluation of Ad5CMV-p53 in vitro and in vivo. Hum Gene Ther 1995;6(2):155-64
   PubMed Web of Science ®Google Scholar
• Lang FF, Yung WK, Sawaya R, Tofilon PJ. Adenovirus-mediated p53 gene therapy for human gliomas. Neurosurgery 1999;45(5):1093-104
   PubMed Web of Science ®Google Scholar
• Vecil GG, Lang FF. Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J Neurooncol 2003;65(3):237-46
   PubMed Web of Science ®Google Scholar
• Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003;21(13):2508-18
   PubMed Web of Science ®Google Scholar
• Kuriyama N, Kuriyama H, Julin CM, et al. Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. Hum Gene Ther 2000;11(16):2219-30
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee YS, Kim H, et al. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst 2006;98(20):1482-93
   PubMed Web of Science ®Google Scholar
• Mok W, Boucher Y, Jain RK. Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res 2007;67(22):10664-8
   PubMed Web of Science ®Google Scholar
• Trask TW, Trask RP, Aguilar-cordova E, et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 2000;1(2):195-203
   PubMed Web of Science ®Google Scholar
• Sandmair AM, Loimas S, Puranen P, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000;11(16):2197-205
   PubMed Web of Science ®Google Scholar
• Germano IM, Fable J, Gultekin SH, Silvers A. Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a Phase I trial in patients with recurrent malignant gliomas. J Neurooncol 2003;65(3):279-89
   PubMed Web of Science ®Google Scholar
• Immonen A, Vapalahti M, Tyynela K, et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 2004;10(5):967-72
   PubMed Web of Science ®Google Scholar
• Wildner O, Morris JC, Vahanian NN, et al. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther 1999;6(1):57-62
   PubMed Web of Science ®Google Scholar
• Nanda D, Vogels R, Havenga M, et al. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res 2001;61(24):8743-50
   PubMed Web of Science ®Google Scholar
• Sonabend AM, Ulasov IV, Lesniak MS. Conditionally replicative adenoviral vectors for malignant glioma. Rev Med Virol 2006;16(2):99-115
   PubMed Web of Science ®Google Scholar
• Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3(6):639-45
   PubMed Web of Science ®Google Scholar
• Fueyo J, Gomez-manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000;19(1):2-12
   PubMed Web of Science ®Google Scholar
• Suzuki K, Fueyo J, Krasnykh V, et al. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001;7(1):120-6
   PubMed Web of Science ®Google Scholar
• Miller CR, Buchsbaum DJ, Reynolds PN, et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998;58(24):5738-48
   PubMed Web of Science ®Google Scholar
• van Beusechem VW, Grill J, Mastenbroel Dc, et al. Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. J Virol 2002;76(6):2753-62
   PubMed Web of Science ®Google Scholar
• Kohno S, Nakagawa K, Hamada K, et al. Midkine promoter-based conditionally replicative adenovirus for malignant glioma therapy. Oncol Rep 2004;12(1):73-8
   PubMed Web of Science ®Google Scholar
• Parr MJ, Manome Y, Tanaka T, et al. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med 1997;3(10):1145-9
   PubMed Web of Science ®Google Scholar
• Shinoura N, Saito K, Yoshida Y, et al. Adenovirus-mediated transfer of Bax with caspase-8 controlled by myelin basic protein promoter exerts an enhanced cytotoxic effect in gliomas. Cancer Gene Ther 2000;7(5):739-48
   PubMed Web of Science ®Google Scholar
• Vandier D, Rixe O, Besnard F, et al. Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter. Cancer Gene Ther 2000;7(8):1120-6
   PubMed Web of Science ®Google Scholar
• McCormick F. Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015. Semin Cancer Biol 2000;10(6):453-9
   PubMed Web of Science ®Google Scholar
• Heise CC, Williams AM, Xue S, et al. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res 1999;59(11):2623-8
   PubMed Web of Science ®Google Scholar
• Chiocca EA, Abbed KM, Tatter S, et al. A Phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004;10(5):958-66
   PubMed Web of Science ®Google Scholar
• Alonso MM, Cascallo M, Gomez-manzano C, et al. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. Cancer Res 2007;67(17):8255-63
   PubMed Web of Science ®Google Scholar
• Miyao Y, Shimizu K, Tamura M, et al. Usefulness of a mouse myelin basic protein promoter for gene therapy of malignant glioma: myelin basic protein promoter is strongly active in human malignant glioma cells. Jpn J Cancer Res 1997;88(7):678-86
   PubMedGoogle Scholar
• Boyd M, Mairs RJ, Mairs SC, et al. Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [131I]MIBG and clonogenic cell kill. Oncogene 2001;20(53):7804-8
   PubMed Web of Science ®Google Scholar
• Komata T, Kondo Y, Kanzawa T, et al. Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells. Hum Gene Ther 2002;13(9):1015-25
   PubMed Web of Science ®Google Scholar
• Kajiwara Y, Yamasaki F, Hama S, et al. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 2003;97(4):1077-83
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-demasters BK, Heinz D, Mccarthy PJ, et al. Survivin in glioblastomas. Protein and messenger RNA expression and comparison with telomerase levels. Arch Pathol Lab Med 2003;127(7):826-33
   PubMed Web of Science ®Google Scholar
• Ulasov IV, Rivera AA, Sonabend AM, et al. Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy. Cancer Biol Ther 2007;6(5):679-85
   PubMed Web of Science ®Google Scholar
• Zhu ZB, Makhija SK, Lu B, et al. Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo. Int J Oncol 2005;27(1):237-46
   PubMed Web of Science ®Google Scholar
• Van Houdt WJ, Haviv YS, Lu B, et al. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J Neurosurg 2006;104(4):583-92
   PubMed Web of Science ®Google Scholar
• Ulasov IV, Zhu ZB, Tyler MA, et al. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther 2007;18(7):589-602
   PubMed Web of Science ®Google Scholar
• Nandi S, Ulasov IV, Tyler MA, et al. Low-dose radiation enhances survivin mediated virotherapy against malignant glioma stem cells. Cancer Res 2008;68(14):5778-84
   PubMed Web of Science ®Google Scholar
• Wohlfahrt ME, Beard BC, Lieber A, Kiem HP. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models. Cancer Res 2007;67(18):8783-90
   PubMed Web of Science ®Google Scholar
• Dent P, Yacoub A, Park M, et al. Searching for a cure: gene therapy for glioblastoma. Cancer Biol Ther 2008;7(9):1335-40
   PubMed Web of Science ®Google Scholar
• Ulasov IV, Sonabend AM, Nandi S, et al. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. Br J Cancer 2009;100(7):1154-64
   PubMed Web of Science ®Google Scholar
• Sonabend AM, Ulasov IV, Tyler MA, et al. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 2008;26(3):831-41
   PubMed Web of Science ®Google Scholar
• Tyler MA, Ulasov IV, Sonabend AM, et al. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther 2009;16(2):262-78
   PubMed Web of Science ®Google Scholar
• Aboody KS, Najbauer J, Danks MK. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 2008;15(10):739-52
   PubMed Web of Science ®Google Scholar
• Donson AM, Foreman NK. Adenovirus mediated gene therapy in a glioblastoma vaccine model; specific antitumor immunity and abrogation of immunosuppression. J Neurooncol 1998;40(3):205-14
   PubMed Web of Science ®Google Scholar
• Munz C, Naumann U, Grimmel C, et al. TGF-β-independent induction of immunogenicity by decorin gene transfer in human malignant glioma cells. Eur J Immunol 1999;29(3):1032-40
   PubMed Web of Science ®Google Scholar
• Wakimoto H, Fulci G, Tyminski E, Chiocca EA. Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther 2004;11(2):214-23
   PubMed Web of Science ®Google Scholar
• Lamfers ML, Fulci G, Gianni D, et al. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol Ther 2006;14(6):779-88
   PubMed Web of Science ®Google Scholar
• Chiocca EA, Smith KM, Mckinney B, et al. A Phase I trial of Ad.hIFN-β gene therapy for glioma. Mol Ther 2008;16(3):618-26
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105(4):1815-22
   PubMed Web of Science ®Google Scholar
• Krampera M, Pasini A, Rigo A, et al. HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. Blood 2005;106(1):59-66
   PubMed Web of Science ®Google Scholar
• Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005;305(1):33-41
   PubMed Web of Science ®Google Scholar
• Zappia E, Casazza S, Pedemonte E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005;106(5):1755-61
   PubMed Web of Science ®Google Scholar
• Spaggiari GM, Capobianco A, Becchetti S, et al. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006;107(4):1484-90
   PubMed Web of Science ®Google Scholar
• New PZ, Baskin D, Trask T, et al. Radiographic and immunologic responses to adjuvant immunotherapy for malignant gliomas. J Clin Oncol (Meeting Abstracts) 2008;26 (15 suppl):2039
   Google Scholar